uniQure N.V. (NasdaqGS: QURE)
Health Care · Biotechnology · NL
$46.52
-3.82% today · +211.1% 1Y
uniQure N.V. (NasdaqGS: QURE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.36B and employs 221 people.
Over the last twelve months the share price has gained 211.1%, trading between 8.73 and 71.50.
Tweenvest scores uniQure N.V. across four factors: quality 34/100, value 55/100, growth 0/100. Its strongest factor is value.
QURE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.36B
- Revenue (TTM)
- $18.67M
- P/E
- —
- EPS
- -4.04
- Dividend yield
- —
- Beta (5Y)
- 0.94
- 52-week high
- $71.50
- 52-week low
- $8.73
- Avg volume (3M)
- —
- Shares outstanding
- 69.37M
- Employees
- 221
- Next earnings
- —
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- ISIN
- NL0010696654
- Founded
- 1998
- Listed since
- Feb 5, 2014
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.